Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
LIVONIA, Mich., Oct. 26, 2016 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia and NAFLD/NASH (nonalcoholic fatty liver disease), today announced that it will issue a press release announcing financial results for the third quarter ended September 30, 2016 on Wednesday, November 2.
The Company also announced that Mina Sooch, Gemphire’s CEO, will be presenting at the 25th Annual Credit Suisse 2016 Healthcare Conference, being held at the Phoenician Hotel in Scottsdale, Arizona, November 7-8.
| 25th Annual Credit Suisse Healthcare Conference Presentation Details: | |
| Date: | Monday, November 7 |
| Time: | 10:00am Mountain Time/12:00pm Eastern Time |
| Location: | Phoenician Hotel, Ballroom G |
The presentation slides will be available immediately prior to and for 90 days following the presentation on the Investors and Media page of Gemphire’s website at http://ir.gemphire.com.
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease). Please visit www.gemphire.com for more information.
Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics (734)-245-1700
